AIIMS director Randeep Guleria on July 20, announced that the institute is going to start Phase 1 human trials for a coronavirus vaccine.
The vaccine has been developed by the Hyderabad-based pharmaceutical company in collaboration with the National Institute of Virology (NIV) and the Indian Council of Medical Research (ICMR). AIIMS, Delhi, was selected by the ICMR for conducting phase I and II trials. COVAXIN has been derived from a strain of the novel coronavirus isolated by the National Institute of Virology in Pune.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.